FILING ANALYSIS · TUESDAY, NOVEMBER 10
PepGen Inc. PEPG — 8-K: Results of Operations and Financial Condition
positive
PepGen announced positive Phase 2 FREEDOM2-DM1 10mg/kg results, demonstrating the highest reported splicing correction and improvements across multiple functional measures, with no treatment discontinuations or serious adverse events, and the 12.5 mg/kg cohort is fully enrolled with results expected in 1H 2027. The company also reported having $104.8M of cash as of September 30, 2026, sufficient t
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →